Navigation Links
PLC in Medical News

Canada Grants PLC Systems First Patent for RenalGuard(R)

FRANKLIN, Mass., July 27 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced it has been issued a patent for the real-time fluid balancing capabilities provided by ...

Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment

NEW BRUNSWICK, N.J. and DUBLIN, July 2 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) and Elan Corporation plc (NYSE: ELN ) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheime...

Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany

Additional Group of Compounds and Enhanced Research Activities Added to Agreement NAPA, Calif., June 8 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced a s...

Carnival Corporation & plc Reports Financial Impact of Itinerary Changes Responding to H1N1 Influenza Mexico Travel Advisory; Plans Rapid Return to Popular Mexican Ports

MIAMI, May 18 /PRNewswire-FirstCall/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE CUK) today announced a financial impact estimated at approximately $0.05 per share, the majority of which will be incurred in the second fiscal quarter of 2009, as a result of modifications to cruise itiner...

Senetek PLC Reports First Quarter 2009 Financial Results

NAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced results for the quarter ended March 31, 2009. Revenue for the quarter ended March 31,...

Allscripts Announces Final Tax Treatment of Special Cash Dividend From the Transactions With Misys plc Completed in October 2008

CHICAGO, April 9 /PRNewswire-FirstCall/ -- Allscripts-Misys Healthcare Solutions, Inc. ("Allscripts") announced today information related to the federal income tax treatment of the special dividend of $5.23 per share distributed in connection with the transactions Allscripts consummated with Misys...

Senetek PLC Reports 2008 Financial Results

Media Attention Builds for Pyratine-6(TM) and Pyratine XR(TM) NAPA, Calif., March 31 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced results for the fourth...

Medicsight PLC Provides Business Update

NEW YORK, Feb. 24 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (NYSE Alternext US: MGT) and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, which assists radiologists in the early detection of disease, ...

Medicsight PLC Restructures Management Team

NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (NYSE-A: MGT) and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, which assists radiologists in the early detection of disease, today annou...

Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance

NEW YORK, Jan. 20 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (NYSE-A: MGT), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, which assists radiologists in the early detection of disease, announces ...
PLC in Medical Technology

Senetek PLC Launches Dedicated Pyratine-6(TM) Website

NAPA, Calif., Jan. 27 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, announced today the launch of a dedicated Pyratine-6(TM) website, http://www.Pyratine-6.com , t...

Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura

ESSEX, United Kingdom, Oct. 24 /PRNewswire-FirstCall/ -- Minster Pharmaceuticals plc (AIM: MPM), the drug development company specializing in neurological and psychiatric disorders, is pleased to announce positive results from its Phase II trial in Denmark of tonabersat in the prevention of mi...

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder

NEW YORK and BUDAPEST, Hungary, Sept. 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Gedeon Richter Plc today announced preliminary top-line results from a phase II clinical trial of cariprazine (RGH-188), an investigational antipsychotic, in patients with acute mania...

Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis

LONDON, June 24 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has initiated a Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from all...

Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis

LONDON, June 11 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study o...

Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea

Accepted for Presentation at the International Investigative Congress of Dermatology at May 2008 meeting in Kyoto, Japan NAPA, Calif., May 5 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that tar...

Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients

LONDON, Jan. 16 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, today announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic...

Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis

LONDON, Oct. 23 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the initiation of a Phase I tolerance study of MRX-4 in 16 patients suffering from allergic rhinitis (AR). The randomized, pl...

ACRIN Study Endorses Virtual Colonoscopy - Validation for Colon CAD Software Maker Medicsight plc

NEW YORK, Oct. 3 /PRNewswire-FirstCall/ -- MGT Capital Investments, Inc. (Amex: MGT ), an investment company focused on the Healthcare Information Technology ("HCIT") sector, announced today that the ACRIN study endorses virtual colonoscopy for Medicsight PLC (subsidiary of MGT). Medicsight P...

Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404

LONDON and FLORENCE, Italy - 8 March 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces positive initial findings from its second, confirmatory phase II trial of AS1404 in non-small cell lung cancer. This 30-patient trial tested an 1800 mg/m2 dose of AS1404 in co...
PLC in Biological News

Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB

... LONDON and SAN DIEGO, April 2, 2009 University College London Business plc (UCLB) and Ocera Therapeutics Inc., a privately held biopharmaceutical company, announced the signing of an exclusive worldwide licensing agreement fo...

Court Approves Scheme of Arrangement

...nnsylvania, May 22 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY ), the global specialty ...t approved the scheme of arrangement between Shire plc and its ordinary shareholders at a hearing today. ...ve one Shire Limited ordinary share for each Shire plc ordinary share they hold at 5.30 p.m. (GMT) on 22 ...

Secure Services Corp. Achieves Milestone in United States Identity Protection with the Launch of the SSC SHAPE Card Management Solution

...health care. For more information about Secure Services Corp., visit secureservicescorp.com or call 1.877.772.1123. About Intercede Intercede Group plc is a leading developer and supplier of smart card and identity management software listed on the London Stock Exchange (IGP LN) (IGP.L). Intercede's M...

Shell Provides Consumers Gasoline Industry's First Pay By Touch Technology at the Pump

...ended) for a description of certain important factors, risks and uncertainties that may affect the Shell Group's businesses. Neither Royal Dutch Shell plc nor any member of the Shell Group undertakes any obligation to publicly update or revise any of these forward-looking statements, whether to reflect n...

Cell wall of pneumonia bacteria can cause brain and heart damage

...ial uptake into these cells. Furthermore, the researchers succeeded in blocking a key enzyme of this pathway in cardiomyoctyes using a molecule called plc inhibitor U73122. The treatment prevented the cell from taking up the fragments but did not appear to interfere with the cell's normal functions. This...

Canada approves marijuana-based pain spray

...duced pain-related sleep disturbance. Principal components A product resulting from the pioneering research efforts of UK-based GW Pharmaceuticals plc and marketed in Canada by Bayer HealthCare, Pharmaceuticals Division, Sativex is the first product indicated in Canada as adjunctive treatment for the...
PLC in Biological Technology

ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated

ADDISON, Texas, June 24 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU ) today announced that at this time discussions to acquire York Pharma, plc, a public limited company incorporated under the laws of England and Wales ("York") have been terminated. Previously it had been announced ...

Senetek PLC Investor Hotline Goes Live

Call 877-SENETEK or 707-259-6278 NAPA, Calif., May 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, announced that an up-to-date audio recording of Company news an...

Senetek PLC Announces New Investor Communication Hotline

NAPA, Calif., April 1 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced plans for the creation of a new communication hotline for the expressed purpose of ...

Senetek PLC Announces 2008 Annual General Meeting Voting Results

NAPA, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that shareholders have approved all four resolutions that the Company had proposed a...

Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology

NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sci...

Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP

RADNOR, Pa., Dec. 11 /PRNewswire/ -- The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP: Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of New York on beha...

Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients

LONDON and NEW YORK, Nov. 6 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhi...

Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

LONDON and NEW YORK, Oct. 30 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that Dr. Yuval Cohen, President of Morria, will deliver a presentation at the Rodman & Renshaw 10th A...

Trinity Biotech plc to Announce Third Quarter 2008 Financial Results on October 31, 2008

Conference Call Scheduled for October 31, 2008 at 11:00 am EASTERN DUBLIN, Ireland, Oct. 23 /PRNewswire-FirstCall/ -- Trinity Biotech plc (Nasdaq: TRIB ), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financia...

Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds

LONDON, Oct. 7 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, announced today the results of the ongoing screening of its novel anti-inflammatory drugs using MD Biosciences' Immunoprofiler(TM) in vitro scr...
PLC in Biological Dictionary

Meristem

... services. ... QUICK FINDER ... DANGOTE SUGAR REFINERY PLC: Q109 RESULTS: OUR INITIAL REACTION ... NIGERIA EQUITY REPORT-UPDATE ON UNILEVER NIGERIA plc (MARCH 26, 2009) ... meristem ( ) n. The undifferentiated plant tissue from which new cells are formed, as that at ... from differentiated ...
Other Tags
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... Barbara, CA (PRWEB) October 31, 2014 ... holiday shoppers to find affordable but tasteful gifts for the ... 22nd Annual Early Bird Gift Giving Special , which ... off when they purchase Wine Club Gift membership. , ... take advantage of this special. Besides offering discounts, Gold Medal ...
(Date:10/31/2014)... drug combination that can trigger the self-destruct process in ... treatments, according to research that will be presented at ... Liverpool next week*. , When healthy cells are no ... in self destruction. But cancer cells swerve away from ... cells grow out of control – causing tumours to ...
(Date:10/31/2014)... October 31, 2014 Triple Board Certified ... hair restoration services to transform the appearance of military ... American Academy of Facial Plastic and Reconstruction Surgery (AAFPRS) ... to restore the facial hair Jones lost during an ... The pro-bono hair restoration procedure, valued around $16,000, took ...
(Date:10/31/2014)... Radiology and EMR Integration , ... between diagnostic imaging centers but Connectivity is Opportunity,” ... “Differentiation is critical in all businesses today ... consider the intense competition and the downward pressure ... stand-out from the competition by fully integrating with ...
Breaking Medicine News(10 mins):Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
(Date:10/30/2014)... bioengineering professor has received a $1.04 million grant ... cartilage tissue and reduce osteoarthritis using a patient,s ... microscaffolding made of biodegradable polymers., Liping Tang, a ... department, said the research is primarily focused on ... battlefield., "We,ve found that if we inject microscaffolding ...
(Date:10/30/2014)... Rochelle, NY, October 30, 2014—Oligonucleotide-based therapeutics present unique ... to cause reproductive and developmental harm. New consensus ... the combined chemical and biological characteristics of these ... Therapeutics , a peer-reviewed journal from Mary ... available free on the Nucleic Acid Therapeutics ...
(Date:10/30/2014)... New York | Heidelberg, 30 October 2014 Biological ... a better understanding of adsorption of solution ions ... biological cells. Now, a new study provides a ... and surrounding solution ions. Joanna Kotyńska and Zbigniew ... the authors of a study describing these findings, ...
Breaking Biology News(10 mins):UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Ion adsorption matter in biology 2
Other Contents